MonoGen, Inc.
TSX : MOG

MonoGen, Inc.

January 29, 2007 09:10 ET

MonoGen Hires Former Abbott Diagnostics Marketing Executive James Cureton as Vice President of Sales and Marketing

MONTREAL, QUEBEC--(CCNMatthews - Jan. 29, 2007) - This Press Release is Not for Distribution in the United States

MonoGen, Inc. ("Corporation") (TSX:MOG) today announced that it entered into an employment agreement with James D. Cureton for the position of Vice President, Sales and Marketing.

Mr. Cureton, with more than 26 years of experience in the diagnostic marketplace, has a proven marketing and sales management track record involving automated diagnostic instrumentation and reagent systems, immunoassays, molecular pathology, oncology, and digital telepathology. Most recently, Mr. Cureton served as Vice President of Operations for the Technology and Instrument Division of Clarient, Inc. In that role Jim was responsible for completing the timely development of a pathology imaging system and implementing a related commercial distribution agreement.

From 1986 through 2004 Mr. Cureton held several positions of growing significance within the Abbott Diagnostics Division of Abbott Laboratories, culminating in the position of Director of Worldwide Marketing, Abbott Molecular. Before joining Abbott, Mr. Cureton worked as a medical technologist and a supervisor of special chemistry assays in St. Luke's Hospital, Denver, Colorado.

MonoGen CEO, President and Chief Scientific Officer, Norman J. Pressman, Ph.D., stated: "Jim, with his solid experience in cancer diagnostics and imaging systems is an important addition to our expanding MonoGen management team as we begin the commercialization of our FDA-approved MonoPrep® Pap Test and the MonoPrep Processor system. His collaborative management style will facilitate strong and successful working relationships and programs with our distribution partner, Cardinal Health.

With operating headquarters in the United States (Greater Chicago area), MonoGen is a medical device company developing an integrated suite of fully automated devices (the SAVANT LABORATORY SYSTEM™) for anatomic and molecular pathology laboratories. The SAVANT LABORATORY SYSTEM™ is being designed to automate processes performed by clinical laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.

The common shares of the Corporation are listed for trading on the Toronto Stock Exchange under the trading symbol "MOG".

Forward-Looking Statements

This press release is not for distribution in the United States.
This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements.

Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while maintaining at all times its various regulatory approvals, the performance of its strategic partners including the performance of Cardinal Health in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information

  • MonoGen, Inc.
    Mr. Andre Denis
    Executive Chairman and Interim Chief Financial Officer
    514-286-0999, ext. 224
    514-286-3777 (FAX)
    adenis@monogen.com